Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy-a retrospective, single-centre study.
acute promyelocytic leukaemia
all-trans retinoic acid
arsenic trioxide
real-world data
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
revised:
05
12
2022
received:
15
11
2022
accepted:
07
12
2022
medline:
6
4
2023
pubmed:
19
12
2022
entrez:
18
12
2022
Statut:
ppublish
Résumé
Arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) form the backbone of the treatment of acute promyelocytic leukaemia (APL), with the addition of chemotherapy for high-risk patients. We describe our experience of treating patients with APL of all risk classes with ATO and ATRA without chemotherapeutic agents. Patients received induction with ATO and ATRA followed by three cycles of consolidation with ATO and ATRA (each 1 month apart) after achieving morphological remission. Patients with intermediate- and high-risk disease received a further 2 years of maintenance with ATRA, 6-mercaptopurine and methotrexate. A total of 206 patients were included in the study. The majority of the patients were intermediate risk (51.9%), followed by high risk (43.2%). Differentiation syndrome was seen in 41 patients (19.9%). Overall, 25 patients (12.1%) died within 7 days of initiating therapy. Seven patients relapsed during follow-up. The mean (SD) estimated 5-year event-free survival (EFS) and overall survival (OS) in the entire cohort was 79% [5.8%] and 80% [5.8%] respectively. After excluding patients who died within 7 days of therapy initiation, the mean (SD) estimated 5-year EFS and OS was 90% [5.8%] and 93% [3.9%] respectively. Our study shows that treatment of all risk classes of APL with ATO and ATRA without chemotherapy is associated with excellent long-term outcomes in the real-world setting.
Substances chimiques
Arsenic Trioxide
S7V92P67HO
Arsenicals
0
Oxides
0
Tretinoin
5688UTC01R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-255Informations de copyright
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
Références
Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, et al. Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet. Blood. 2019;133(15):1630-43. https://doi.org/10.1182/BLOOD-2019-01-894980
Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and lymphoma group (ALLG) APML4 study: a non-randomised phase 2 trial. Lancet Haematol. 2015;2(9):e357-66. https://doi.org/10.1016/S2352-3026(15)00115-5
Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16(13):1295-305. https://doi.org/10.1016/S1470-2045(15)00193-X
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, et al. Long-term outcome of acute promyelocytic leukemia treated with all- trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017;129(10):1275-83. https://doi.org/10.1182/BLOOD-2016-09-736686
Ravandi F, Kantarjian H. Time to abandon traditional chemotherapy for acute promyelocytic leukaemia? Lancet Oncol. 2015;16(13):1274-5. https://doi.org/10.1016/S1470-2045(15)00210-7
Bankar A, Korula A, Kulkarni UP, Devasia AJ, NA F, Lionel S, et al. Resource utilization and cost effectiveness of treating acute promyelocytic leukaemia using generic arsenic trioxide. Br J Haematol. 2020;189(2):269-78. https://doi.org/10.1111/BJH.16343
Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-4. https://doi.org/10.1111/J.1538-7836.2005.01204.X
Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med. 1992;117(4):292-6. https://doi.org/10.7326/0003-4819-117-4-292
Dayama A, Dass J, Seth T, Mahapatra M, Mishra PC, Saxena R. Clinico-hematological profile and outcome of acute promyelocytic leukemia patients at a tertiary care center in North India. Indian J Cancer. 2015;52(3):309-12. https://doi.org/10.4103/0019-509X.176731
Kulkarni UP, Selvarajan S, Lionel S, Prakash MA, Palani HK, Balasundaram N, et al. Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia. Blood Cancer J. 2022;12(1):22. https://doi.org/10.1038/S41408-022-00619-3
Yedla RP, Bala SC, Pydi VR, Kuruva SP, Chennamaneni R, Konatam ML, et al. Outcomes in adult acute promyelocytic leukemia: a decade experience. Clin Lymphoma Myeloma Leuk. 2020;20(4):e158-64. https://doi.org/10.1016/J.CLML.2019.12.011
Lancet JE, Moseley AB, Coutre SE, DeAngelo DJ, Othus M, Tallman MS, et al. A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535). Blood Adv. 2020;4(8):1683-9. https://doi.org/10.1182/BLOODADVANCES.2019001278
Vaid T, Aggarwal M, Dass J, Dhawan R, Kumar P, Viswanathan GK, et al. Shifting gears to differentiation agents in acute promyelocytic leukemia with resource constraints-a cohort study. Acta Oncol. 2022;11:1-6. https://doi.org/10.1080/0284186X.2022.2109424
Jain H, Rengaraj K, Sharma V, Bonda A, Chanana R, Thorat J, et al. Infection prevalence in adolescents and adults with acute myeloid leukemia treated in an Indian tertiary care center. JCO Glob Oncol. 2020;6(6):1684-95. https://doi.org/10.1200/GO.20.00240
Dhakal P, Lyden E, Rajasurya V, Zeidan AM, Chaulagain C, Gundabolu K, et al. Early mortality and overall survival in acute promyelocytic leukemia: do real-world data match results of the clinical trials? Leuk Lymphoma. 2021;62(8):1949-57. https://doi.org/10.1080/10428194.2021.1894651
Golamari K, Mikkilineni A, Chappidi S. Early death in acute promyelocytic leukemia: evidence from a rural cancer center. Indian J Cancer. 2020;57(4):451-6. https://doi.org/10.4103/IJC.IJC_177_19
Roy PS, Munikoty V, Trehan A, Jain R, Bhatia P, Naseem S, et al. Early mortality continues to be a barrier to excellent survival in childhood acute promyelocytic leukemia: a retrospective study of 62 patients spanning 17 years. Pediatr Hematol Oncol. 2022;1-14. https://doi.org/10.1080/08880018.2022.2082610
Karunakaran P, Yanamandra U, Nampoothiri R v, et al. Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia. Br J Haematol. 2019;184(4):672-3. https://doi.org/10.1111/BJH.15153
Yanamandra U, Karunakaran P, Khadwal A, Prakash G, Lad D, Naseem S, et al. Invasive fungal infections in acute promyelocytic leukemia on dual differentiating agents: real world data. Indian J Hematol Blood Transfus. 2018;34(3):466-8. https://doi.org/10.1007/S12288-017-0894-9
Deka RR, Naseem S, Bhatia P, Binota J, Sonam P, Rana P, et al. FLT3-ITD mutation does not influence survival outcome in adult acute promyelocytic leukemia patients treated with ATO and ATRA-based therapeutic regimen: experience from a north Indian tertiary care Centre. Clin Lymphoma Myeloma Leuk. 2022;22(6):416-23. https://doi.org/10.1016/J.CLML.2021.12.007